ARK Investment Management LLC grew its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 78.8% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,234 shares of the biopharmaceutical company’s stock after purchasing an additional 544 shares during the period. ARK Investment Management LLC’s holdings in Regeneron Pharmaceuticals were worth $606,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Sterling Investment Advisors Ltd. grew its position in Regeneron Pharmaceuticals by 11.2% in the 2nd quarter. Sterling Investment Advisors Ltd. now owns 278 shares of the biopharmaceutical company’s stock worth $137,000 after purchasing an additional 28 shares during the last quarter. FNY Partners Fund LP grew its position in Regeneron Pharmaceuticals by 200.0% in the 2nd quarter. FNY Partners Fund LP now owns 300 shares of the biopharmaceutical company’s stock worth $147,000 after purchasing an additional 200 shares during the last quarter. FNY Managed Accounts LLC acquired a new stake in Regeneron Pharmaceuticals in the 1st quarter worth $140,000. Alpha Windward LLC grew its position in Regeneron Pharmaceuticals by 0.3% in the 2nd quarter. Alpha Windward LLC now owns 384 shares of the biopharmaceutical company’s stock worth $189,000 after purchasing an additional 1 shares during the last quarter. Finally, IFP Advisors Inc grew its position in Regeneron Pharmaceuticals by 33.2% in the 2nd quarter. IFP Advisors Inc now owns 385 shares of the biopharmaceutical company’s stock worth $189,000 after purchasing an additional 96 shares during the last quarter. Institutional investors own 67.94% of the company’s stock.

Regeneron Pharmaceuticals, Inc. (NASDAQ REGN) traded down 0.17% during midday trading on Friday, reaching $432.72. 626,312 shares of the company’s stock traded hands. The company has a market cap of $45.88 billion, a P/E ratio of 43.41 and a beta of 1.65. The stock has a 50-day moving average of $468.97 and a 200 day moving average of $447.18. Regeneron Pharmaceuticals, Inc. has a 52-week low of $325.35 and a 52-week high of $543.55.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its earnings results on Thursday, August 3rd. The biopharmaceutical company reported $4.17 EPS for the quarter, topping analysts’ consensus estimates of $2.67 by $1.50. The firm had revenue of $1.47 billion during the quarter, compared to analysts’ expectations of $1.36 billion. Regeneron Pharmaceuticals had a net margin of 22.05% and a return on equity of 25.58%. The business’s revenue for the quarter was up 21.2% compared to the same quarter last year. During the same quarter in the prior year, the business earned $2.82 earnings per share. On average, analysts anticipate that Regeneron Pharmaceuticals, Inc. will post $14.89 earnings per share for the current fiscal year.

TRADEMARK VIOLATION WARNING: “Regeneron Pharmaceuticals, Inc. (REGN) Shares Bought by ARK Investment Management LLC” was first reported by Watch List News and is owned by of Watch List News. If you are reading this piece of content on another website, it was illegally copied and reposted in violation of U.S. & international copyright legislation. The original version of this piece of content can be accessed at https://www.watchlistnews.com/regeneron-pharmaceuticals-inc-regn-shares-bought-by-ark-investment-management-llc/1582898.html.

Several analysts have issued reports on the stock. Leerink Swann restated an “outperform” rating and issued a $573.00 price target on shares of Regeneron Pharmaceuticals in a research report on Thursday, June 22nd. Raymond James Financial, Inc. restated an “outperform” rating and issued a $547.00 price target (up from $475.00) on shares of Regeneron Pharmaceuticals in a research report on Thursday, June 22nd. BMO Capital Markets restated a “market perform” rating and issued a $484.00 price target (up from $421.00) on shares of Regeneron Pharmaceuticals in a research report on Friday, July 21st. Bank of America Corporation restated a “buy” rating and issued a $593.00 price target (up from $589.00) on shares of Regeneron Pharmaceuticals in a research report on Friday, July 21st. Finally, Sanford C. Bernstein lowered shares of Regeneron Pharmaceuticals from an “outperform” rating to a “market perform” rating and raised their price target for the stock from $410.00 to $480.00 in a research report on Monday, June 26th. They noted that the move was a valuation call. Two equities research analysts have rated the stock with a sell rating, thirteen have assigned a hold rating, twelve have issued a buy rating and two have issued a strong buy rating to the company’s stock. The stock has an average rating of “Hold” and an average price target of $490.03.

In related news, SVP Robert E. Landry sold 663 shares of the firm’s stock in a transaction that occurred on Wednesday, September 6th. The shares were sold at an average price of $498.60, for a total value of $330,571.80. Following the completion of the transaction, the senior vice president now owns 10,099 shares in the company, valued at approximately $5,035,361.40. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Also, CFO Robert E. Landry sold 189 shares of the firm’s stock in a transaction that occurred on Tuesday, September 5th. The shares were sold at an average price of $501.06, for a total transaction of $94,700.34. Following the completion of the transaction, the chief financial officer now owns 10,099 shares of the company’s stock, valued at approximately $5,060,204.94. The disclosure for this sale can be found here. Insiders sold 85,968 shares of company stock valued at $40,699,948 in the last three months. Company insiders own 10.40% of the company’s stock.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.

Institutional Ownership by Quarter for Regeneron Pharmaceuticals (NASDAQ:REGN)

Receive News & Ratings for Regeneron Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.